Neurocrine Biosciences Raises FY 2026 INGREZZA Net Product Sales Guidance from $2.825B-$2.875B to $2.900B-$2.925B
Benzinga Newsdesk 3 hours ago
NewsGuidance
Neurocrine Biosciences (NASDAQ:NBIX) Raises FY 2026 INGREZZA Net Product Sales Guidance from $2.825B-$2.875B to $2.900B-$2.925B
Neurocrine Biosciences (NASDAQ:NBIX) Raises FY 2026 INGREZZA Net Product Sales Guidance from $2.825B-$2.875B to $2.900B-$2.925B